Effect of Doxepin and Nortriptyline on Irritable Bowel Syndrome
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Phase
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Qom, Iran, Islamic Republic of, 1677859642
- Gastrointestinal Research center,Beheshti Hospital
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Presence of diarrhea predominant irritable bowel syndrome according to ROME criteria
Exclusion Criteria:
- Gastrointestinal bleeding
- More than 5% weight loss in the last 6 months
- Presence of any finding in favor of organic disorders in the lab tests or organic disorder in colonoscopy of high risk patients
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Placebo Comparator: placebo
|
|
|
Active Comparator: doxepin
|
|
|
Active Comparator: nortriptyline
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Study record dates
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Digestive System Diseases
- Pathologic Processes
- Disease
- Gastrointestinal Diseases
- Colonic Diseases, Functional
- Colonic Diseases
- Intestinal Diseases
- Syndrome
- Irritable Bowel Syndrome
- Physiological Effects of Drugs
- Adrenergic Agents
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Central Nervous System Depressants
- Psychotropic Drugs
- Neurotransmitter Uptake Inhibitors
- Membrane Transport Modulators
- Antidepressive Agents
- Hypnotics and Sedatives
- Antidepressive Agents, Tricyclic
- Sleep Aids, Pharmaceutical
- Histamine Antagonists
- Histamine Agents
- Adrenergic Uptake Inhibitors
- Nortriptyline
- Doxepin
Other Study ID Numbers
Other Study ID Numbers
- YRC-1246
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.